US2004229912A1PendingUtilityA1

Polymeric delivery formulations of leuprolide with improved efficacy

59
Assignee: ATRIX LAB INCPriority: Oct 28, 1998Filed: Jun 21, 2004Published: Nov 18, 2004
Est. expiryOct 28, 2018(expired)· nominal 20-yr term from priority
Inventors:Richard L. DunnJohn Steven GarrettHarish RavivarapuBhagya L. Chandrashekar
A61P 35/00A61P 5/00A61P 5/06A61P 5/04A61P 5/24A61P 43/00A61P 13/08A61P 15/00A61P 15/08A61K 9/19A61K 9/0019A61K 38/09A61K 47/22B65D 81/3205A61K 9/0024A61K 47/34
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.

Claims

exact text as granted — not AI-modified
1 . A flowable composition suitable for use as a controlled release implant, the composition comprising: 
 (a) a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid;    (b) a biocompatible polar aprotic solvent selected from the group consisting of an amide, an ester, a carbonate, a ketone, an ether, and a sulfonyl; wherein the biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid; and    (c) leuprolide acetate.    
     
     
         2 - 46  (Cancelled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.